BY OUR PLATFORMS
BY THERAPEUTIC AREA
BY OUR PLATFORMS
ZeClinics' Crispants are a fast-track choice for target validation and disease modeling. These somatic F0 mutants, which carry a high rate of biallelic mutations, enable a high throughput evaluation of loss-of-function phenotypes in a really short time (2-3 months).
Looking for a strategy for in vivo validation of your genes in the context of a disease?
Unlike other alternatives for fast target validation, such as morpholino or ASO knock-downs, the stable genetic modifications of Crispants allow studying biological processes at later stages.
Crispants are also interesting to confirm the expected phenotypic output of your custom mutation before establishing a KO line for further studies, such as drug screening.
Stable mutations: unlike larvae injected with morpholino or antisense oligonucleotides, Crispants do not recover a normal gene expression after the first days of developmentScalable solution: high throughput screening of multiple candidate genesConfirmation of the phenotypic output before establishing the KO lineNon-invasive, in vivo readouts to detect KO-induced phenotypes at the level of cells, tissues or organs
Stable mutations: unlike larvae injected with morpholino or antisense oligonucleotides, Crispants do not recover a normal gene expression after the first days of development
Scalable solution: high throughput screening of multiple candidate genes
Confirmation of the phenotypic output before establishing the KO line
Non-invasive, in vivo readouts to detect KO-induced phenotypes at the level of cells, tissues or organs
We design sgRNAs having high specificity and efficiency to guarantee a mutagenesis rate close to 100%. A specific sgRNA guides the Cas9 endonuclease to the desired locus of interest to induce targeted double-strand breaks. Error-prone mechanisms of DNA repair can cause the generation of small insertions and deletions (INDELs) potentially disrupting the coding sequence of the targeted gene and promoting the formation of loss-of-function mutations.
To generate mutant alleles in zebrafish, the Cas9 and the sgRNA(s) designed against the selected gene are injected into wild-type one-cell-stage embryos (F0). Mutagenesis takes place during the early stages of embryonic development, giving rise to F0 larvae carrying a mosaic set of somatic and germline mutations.
Crispants carrying high rates of mutations in the selected gene are phenotypically preselected. These high mutagenesis rates in somatic KOs enable the evaluation of the resulting loss-of-function phenotypes already in F0 larvae.
Phenotypes resulting from the genetic modification can be characterized on demand in the whole organism or in specific organs:
If you want more information about our Crispantsgeneration services or have any other questions,please contact our experts.